A large, long clinical trial that measures whether a drug changes the rate of real cardiac events (heart attack, stroke, cardiovascular death) not just risk markers like cholesterol. These trials are expensive and take years, so a completed one is a strong evidence signal. Wegovy's SELECT trial is the landmark example in the GLP-1 class, showing reduced major cardiac events in people with existing heart disease.
Related terms: Placebo-controlled trial · Semaglutide · Cardiometabolic
See also: Wegovy vs. Zepbound